Cargando…

Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis

Prospective studies have suggested genetic variation in the neuregulin 1 (NRG1) and 𝒟-amino-acid oxidase activator (DAOA) genes may assist in differentiating high-risk individuals who will or will not transition to psychosis. In a prospective cohort (follow-up=2.4–14.9 years) of 225 individuals at u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bousman, C A, Yung, A R, Pantelis, C, Ellis, J A, Chavez, R A, Nelson, B, Lin, A, Wood, S J, Amminger, G P, Velakoulis, D, McGorry, P D, Everall, I P, Foley, D L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641410/ https://www.ncbi.nlm.nih.gov/pubmed/23632455 http://dx.doi.org/10.1038/tp.2013.23

Ejemplares similares

Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis
por: Tognin, S., et al.
Publicado: (2014)

Gene Polymorphisms and Expression of NRG1, DAOA, and DISC1 Genes in a Chinese Han Population with an Ultra-High Risk for Psychosis
por: He, Xiao-Yan, et al.
Publicado: (2023)

Persistent negative symptoms in individuals at Ultra High Risk for psychosis
por: Yung, Alison R., et al.
Publicado: (2019)

Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
por: Nelson, Barnaby, et al.
Publicado: (2020)

PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia
por: Di Biase, M A, et al.
Publicado: (2017)

Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis
por: Ansell, B. R. E., et al.
Publicado: (2015)

Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis
por: Mechelli, Andrea, et al.
Publicado: (2017)

M22. IGG ANTIBODIES TO TOXOPLASMA GONDII ARE ASSOCIATED WITH INCREASED LONG-TERM RISK FOR PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2020)

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
por: Amminger, G P, et al.
Publicado: (2015)

Erythrocyte glutathione levels as long-term predictor of transition to psychosis
por: Lavoie, S, et al.
Publicado: (2017)

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2018)

Early Intervention in Psychosis: Obvious, Effective, Overdue
por: McGorry, Patrick D.
Publicado: (2015)

White matter integrity in individuals at ultra-high risk for psychosis: a systematic review and discussion of the role of polyunsaturated fatty acids
por: Vijayakumar, Nandita, et al.
Publicado: (2016)

Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits
por: Jagannath, Vinita, et al.
Publicado: (2017)

Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research
por: Nelson, Barnaby, et al.
Publicado: (2018)

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis
por: Berger, Gregor E., et al.
Publicado: (2016)

O1.6. INCREASED COMPLEMENT FACTORS C3 AND C4 IN SCHIZOPHRENIA AND THE EARLY STAGES OF PSYCHOSIS: IMPLICATIONS FOR CLINICAL SYMPTOMATOLOGY AND CORTICAL THICKNESS
por: Cropley, Vanessa, et al.
Publicado: (2018)

Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers
por: Clark, S R, et al.
Publicado: (2016)

DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis
por: Mössner, Rainald, et al.
Publicado: (2009)

Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis
por: Chana, Gursharan, et al.
Publicado: (2013)

T30. TIPPING POINTS – PREDICTING TRANSITIONS TO PSYCHOSIS IN AT-RISK YOUNG PEOPLE
por: Hartmann, Jessica A, et al.
Publicado: (2018)

The need for early intervention for psychosis to persist throughout the COVID-19 pandemic and beyond
por: O’Donoghue, B., et al.
Publicado: (2020)

Discharge destinations for young people with a first episode of psychosis after attending an early intervention for psychosis service
por: O’Donoghue, Brian, et al.
Publicado: (2023)

Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis
por: Schirmbeck, Frederike, et al.
Publicado: (2021)

Negative Symptoms of Psychosis Correlate with Gene Expression of the Wnt/β-Catenin Signaling Pathway in Peripheral Blood
por: Bousman, Chad A., et al.
Publicado: (2013)

Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis
por: Morgan, V. A., et al.
Publicado: (2014)

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
por: Cotton, S. M., et al.
Publicado: (2019)

Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia
por: Mostaid, Md Shaki, et al.
Publicado: (2017)

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
por: Föcking, Melanie, et al.
Publicado: (2016)

Correlates of substance use in a large naturalistic cohort of young people with early and emerging psychosis
por: El-Hage, D., et al.
Publicado: (2023)

“Attenuated psychotic symptoms syndrome” as a risk syndrome of psychosis, diagnosis in DSM-V: The debate
por: Shrivastava, Amresh, et al.
Publicado: (2011)

M21. THE STEP TRIAL: A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMISED TRIAL (SMART) OF INTERVENTIONS FOR PATIENTS AT ULTRA-HIGH RISK OF PSYCHOSIS - STUDY RATIONALE, DESIGN AND BASELINE DATA
por: Nelson, Barnaby, et al.
Publicado: (2020)

Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients
por: Mostaid, Md Shaki, et al.
Publicado: (2017)

4.3 ENHANCING SOCIAL FUNCTIONING AND LONG-TERM RECOVERY IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS (FEP) AND YOUNG PEOPLE AT ULTRA HIGH RISK (UHR) FOR PSYCHOSIS: A NOVEL ONLINE SOCIAL THERAPY APPROACH
por: Alvarez-Jimenez, Mario, et al.
Publicado: (2018)

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
por: Allott, Kelly, et al.
Publicado: (2018)

T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020)

Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients
por: Nieuwenhuis, Mireille, et al.
Publicado: (2017)

T44. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EFFECTS OF VITAMIN B12, B6 AND FOLIC ACID ON COGNITION AND SYMPTOMS IN FIRST-EPISODE PSYCHOSIS: THE VITAMINS IN PSYCHOSIS STUDY
por: Allott, Kelly, et al.
Publicado: (2018)

The Positive and Negative Experiences of Caregiving for Siblings of Young People with First Episode Psychosis
por: Bowman, Siann, et al.
Publicado: (2017)

Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area
por: Weibell, Melissa A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0krtkm9djd104bc02kjqa5uh82